fda compounding semaglutide warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Important Update: Changes to Compounded

No product will let you eat all the food you want and still lose weight. Do your homework Customers signed up for a GLP-1 subscription, not knowing NextMed planned to make undisclosed charges and enforce hidden membership commitments, according to Federal Trade Commission allegations

1 2 "The Origin and Understanding of the Incretin Concept"

DISCUSSION This systematic review, conducted following PRISMA guidelines, evaluated the efficacy of retatrutide (LY3437943) in managing diabetes and obesity

The EU agency estimated that this condition may affect 1 in 10,000 people taking semaglutides for at least one year

Experts recommend staying on the medications long-term

It's time to get the relief you need